不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
白细胞中免疫反应细胞的定量分析有助于诊断由贝沙罗汀引起的药疹
英文原题：Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene.
查看英文原题
Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
贝沙罗汀是一种第三代维A酸X受体选择性维A酸，已被批准用于治疗皮肤T细胞淋巴瘤（CTCL）。由于贝沙罗汀的客观缓解率相对较高，且无种族差异，在真实世界临床实践中，贝沙罗汀可作为光疗抵抗性早期CTCL患者的一线治疗之一。尽管已有贝沙罗汀引起的各种不良事件的报道，但尚无贝沙罗汀引起药疹的报道。可能的原因之一是，在组织学上难以区分药疹与CTCL复发。在本报告中，描述了通过数字显微镜对免疫组化染色进行定量分析而诊断的2例接受贝沙罗汀治疗的CTCL患者的药疹。
展开英文摘要原文
Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of cutaneous T-cell lymphomas (CTCLs). Since the objective response rate of bexarotene is relatively high, with no racial differences, bexarotene can be administered to patients with phototherapy-resistant early CTCL as one of the first-line therapies in real-world clinical practice.
Although various adverse events caused by bexarotene have been reported, there have been no reports of drug eruptions caused by bexarotene. One of the possible reasons is that it is difficult to distinguish a drug eruption from recurrence of CTCL, histologically. In this report, drug eruptions in 2 patients with CTCL treated with bexarotene diagnosed by quantitative analysis of immunohistochemical staining by digital microscopy are described.
论文信息
- 作者
- Chiba H、Kambayashi Y、Ohuchi K、Amagai R、Tamabuchi E、Hashimoto A、Fujimura T
- 单位
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.Japan
- 文献类型
- 病例报告
- 期刊
- Case reports in oncology2022 Jan-Apr
- 原文标识
- PubMed 35221968 · DOI 10.1159/000521843
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →